Topic

All

23
May
2022

Sachi Bioworks: Out of the University, Into Outer Space

When they started their first venture together, Dr. Anushree Chatterjee and Dr. Prashant Nagpal were both leading research labs at the University of Colorado, Boulder. Prashant’s lab focused on nanotechnology and molecular biology: Anushree’s focused on building antibiotics for drug-resistant bacteria.  That startup, Praan Biosciences, was founded in 2014 to develop improved genetic sequencing technology. Anushree and Prashant had one...
Read More
19
May
2022

A Path Forward for More Biotech Workers

Biotech needs more workers. More people who don’t have PhDs and MDs. The industry is 40 years old, and maturing. More companies are developing commercial products. Someone needs to make these products with precision, and at scale. Given the sophisticated nature of the products (cell therapy, gene therapy, advanced biologics, RNA medicines), the fragile global supply chains, and the importance...
Read More
12
May
2022

Changing the Balance of Power

Early in my career as a physician, I took care of a woman who died from complications of an abortion procedure. The patient had traveled to the blue state where I practiced, from a red state where she lived that restricted abortion access, to obtain care she couldn’t find or afford at home. She had previously gotten a procedure performed...
Read More
9
May
2022

Fighting Cancer With Food and Drugs: Lew Cantley and Sid Mukherjee on The Long Run

Today’s guests on The Long Run are Lewis Cantley and Siddhartha Mukherjee. They are co-founders of San Francisco-based Faeth Therapeutics. Cantley, who recently moved to Dana Farber Cancer Institute, is a scientist well-known for his work on cancer metabolism. He discovered the PI3kinase pathway that’s an important regulator of normal cell growth, proliferation, metabolism – and which can become activated...
Read More
5
May
2022

An Old Idea Whose Time Has Come

People are returning to the office. Many are rethinking the basics of work. So many people are exhausted and anxious. Biotech leaders are thinking carefully about how to proceed. An R&D-based industry needs people in environments that allow them to be energized, creative, collaborative. Here’s one simple idea: Walking meetings. The “walk and talk” business meeting isn’t new. But we...
Read More
3
May
2022

Ram Aiyar on Finding Deal Alignment Internally and Externally

Ram Aiyar is currently the CEO of Cambridge, Mass.-based Korro Bio, a company using RNA editing to treat genetic diseases, including Alpha-1 Antitrypsin Deficiency. Before he took that job, he was a founder and executive vice president of corporate and business development at Corvidia Therapeutics. That company was acquired by Novo Nordisk in August 2020 for $725 million upfront, and...
Read More
2
May
2022

Biopharmas: Digitizing, But Not Quite Digital

What a difference two years makes. In January 2020, I left my role as a senior partner at a corporate life-science venture fund to pursue my interest in what I recognized as a captivating frontier: the intersection of biopharma with emerging digital and data technology. I set up an independent consultancy, and advised senior R&D executives in both large and...
Read More
28
Apr
2022

A Big Opportunity in Obesity

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
5
Apr
2022

Samantha Truex on How Getting Market Feedback Turned Into M&A for Padlock

Samantha Truex is the CEO of Upstream Bio, a stealthy developer of drugs for inflammatory diseases with $200 million in backing from a syndicate led by OrbiMed. Before her newest venture, Sam had an impressive career as a business development executive, including as the chief business officer of Cambridge, Mass.-based Padlock Therapeutics. That company, a developer of Protein/Peptidyl Arginine Deiminase...
Read More